Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) was up 8% on Wednesday . The company traded as high as $0.47 and last traded at $0.4545. 341,917 shares changed hands during trading, a decline of 41% from the average session volume of 579,155 shares. The stock had previously closed at $0.4210.
Analyst Ratings Changes
JSPR has been the subject of several research reports. TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Tuesday, April 21st. UBS Group began coverage on shares of Jasper Therapeutics in a research note on Monday, March 23rd. They issued a “neutral” rating for the company. Finally, Royal Bank Of Canada set a $3.00 target price on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a report on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $13.14.
Check Out Our Latest Report on Jasper Therapeutics
Jasper Therapeutics Stock Performance
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08. Equities analysts anticipate that Jasper Therapeutics, Inc. will post -1.67 EPS for the current fiscal year.
Institutional Investors Weigh In On Jasper Therapeutics
A number of large investors have recently added to or reduced their stakes in JSPR. Goldman Sachs Group Inc. raised its position in Jasper Therapeutics by 6,394.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after purchasing an additional 1,719,602 shares during the last quarter. Acorn Capital Advisors LLC bought a new stake in shares of Jasper Therapeutics in the 3rd quarter worth approximately $3,291,000. Velan Capital Investment Management LP increased its stake in shares of Jasper Therapeutics by 86.1% during the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock valued at $6,206,000 after buying an additional 1,234,567 shares during the period. Woodline Partners LP bought a new position in shares of Jasper Therapeutics during the third quarter valued at approximately $2,475,000. Finally, Propel Bio Management LLC bought a new position in shares of Jasper Therapeutics during the third quarter valued at approximately $2,449,000. Institutional investors own 79.85% of the company’s stock.
About Jasper Therapeutics
Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.
Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.
Read More
- Five stocks we like better than Jasper Therapeutics
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
